GAG
TCRT icon

GM Advisory Group’s Alaunos Therapeutics TCRT Stock Holding History

GM Advisory Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-70
Closed -$53K – 70
2014
Q4 		$53K Hold
70
– – 0.03% 75
2014
Q3 		$28K Sell
70
-13
-16% -$6.27K 0.02% 72
2014
Q2 		$50K Hold
83
– – 0.04% 76
2014
Q1 		$51K Hold
83
– – 0.04% 76
2013
Q4 		$54K Buy
+83
New +$49.4K 0.06% 65

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GM Advisory Group's TCRT Position: Q1 2015 in Review

GM Advisory Group sold out of Alaunos Therapeutics (TCRT) in Q1 2015, closing a stake of 70 shares — an estimated $53K sold.

GM Advisory Group first reported a position in TCRT in Q4 2013 and held it in 5 quarters. The position peaked at $54K in Q4 2013. 128 funds tracked by Wall St. Rank hold TCRT as of Q1 2015.

  • GM Advisory Group reported no remaining Alaunos Therapeutics position as of Q1 2015 after selling out during the quarter.
  • GM Advisory Group sold 70 Alaunos Therapeutics shares in Q1 2015, an estimated $53K.
  • GM Advisory Group first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 5 quarters.
  • GM Advisory Group's Alaunos Therapeutics position peaked at $54K in Q4 2013.
  • 128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2015.

Based on GM Advisory Group's 13F filing for Q1 2015, filed 11 May 2015.